Professional Summary
Education & Certifications
- Residency: University of Minnesota School of Medicine (1979) MN
- Internship: University of Minnesota School of Medicine (1978) MN
- Medical Education: Columbia Presbyterian Pediatric Residency Program (1977) NY
-
- Fellowship: Memorial Sloan-Kettering Cancer Center (1984) NY
- Board Certification: American Board of Psychiatry and Neurology, Neurology (1983)
- Residency: New York Presbyterian Hospital (1982) NY
- M.D., Columbia College of P&S, Medicine (1977)
Publications
-
Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: A review of the literature
Colocci, N., Glantz, M., & Recht, L. (2004). Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: A review of the literature. SEMINARS IN NEUROLOGY, 24(4), 395–404. -
Treatment of neoplastic meningitis: what is the standard of care?
Recht, L., & Phuphanich, S. (2004). Treatment of neoplastic meningitis: what is the standard of care? Expert Review of Neurotherapeutics, 4(4), S11–7. -
Amplification of whole tumor genomes and geneby-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA
Bredel, M., Bredel, C., Juric, D., Kim, Y., Vogel, H., Harsh, G. R., … Sikic, B. I. (2005). Amplification of whole tumor genomes and geneby-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. JOURNAL OF MOLECULAR DIAGNOSTICS, 7(2), 171–82. -
-
High-resolution genome-wide mapping of genetic alterations in human glial brain tumors
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., & Sikic, B. I. (2005). High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. CANCER RESEARCH, 65(10), 4088–96. -
Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., & Sikic, B. I. (2005). Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. CANCER RESEARCH, 65(19), 8679–89. -
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappa B-mediated resistance to O-6-alkylating agents in human glioblastomas
Bredel, M., Bredel, C., Juric, D., Duran, G. E., Yu, R. X., Harsh, G. R., … Sikic, B. I. (2006). Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappa B-mediated resistance to O-6-alkylating agents in human glioblastomas. JOURNAL OF CLINICAL ONCOLOGY, 24(2), 274–87. -
Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea
Jang, T. C., Savarese, T., Low, H. P., Kim, S., Vogel, H., Lapointe, D., … Recht, L. (2006). Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea. AMERICAN JOURNAL OF PATHOLOGY, 168(5), 1676–85. -
Optimizing therapy for patients with brain metastases
Kuo, T., & Recht, L. (2006). Optimizing therapy for patients with brain metastases. SEMINARS IN ONCOLOGY, 33(3), 299–306. -
A distinct phenotypic change in gliomas at the time of magnetic resonance imaging detection
Jang, T., Sathy, B., Hsu, Y.-H., Merchant, M., Recht, B., Chang, C., & Recht, L. (2008). A distinct phenotypic change in gliomas at the time of magnetic resonance imaging detection. JOURNAL OF NEUROSURGERY, 108(4), 782–790. -
Murine Embryonic Stem Cell-Derived Pyramidal Neurons Integrate into the Cerebral Cortex and Appropriately Project Axons to Subcortical Targets
Ideguchi, M., Palmer, T. D., Recht, L. D., & Weimann, J. M. (2010). Murine Embryonic Stem Cell-Derived Pyramidal Neurons Integrate into the Cerebral Cortex and Appropriately Project Axons to Subcortical Targets. JOURNAL OF NEUROSCIENCE, 30(3), 894–904. -
Treatment and Prevention of Secondary CNS Lymphoma
Nagpal, S., Glantz, M. J., & Recht, L. (2010). Treatment and Prevention of Secondary CNS Lymphoma. SEMINARS IN NEUROLOGY, 30(3), 263–272. -
5 '-AMP-activated protein kinase activity is elevated early during primary brain tumor development in the rat
Jang, T., Calaoagan, J. M., Kwon, E., Samuelsson, S., Recht, L., & Laderoute, K. R. (2011). 5 '-AMP-activated protein kinase activity is elevated early during primary brain tumor development in the rat. INTERNATIONAL JOURNAL OF CANCER, 128(9), 2230–39. -
Time-lapse imaging of disease progression in deep brain areas using fluorescence microendoscopy
Barretto, R. P. J., Ko, T. H., Jung, J. C., Wang, T. J., Capps, G., Waters, A. C., … Schnitzer, M. J. (2011). Time-lapse imaging of disease progression in deep brain areas using fluorescence microendoscopy. NATURE MEDICINE, 17(2), 223–U120. -
Treatment and Prophylaxis of Hematologic Malignancy in the Central Nervous System
Nagpal, S., & Recht, L. (2011). Treatment and Prophylaxis of Hematologic Malignancy in the Central Nervous System. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 13(4), 400–412. -
Chemerin158K Protein Is the Dominant Chemerin Isoform in Synovial and Cerebrospinal Fluids but Not in Plasma
Zhao, L., Yamaguchi, Y., Sharif, S., Du, X.-Y., Song, J. J., Lee, D. M., … Leung, L. L. K. (2011). Chemerin158K Protein Is the Dominant Chemerin Isoform in Synovial and Cerebrospinal Fluids but Not in Plasma. JOURNAL OF BIOLOGICAL CHEMISTRY, 286(45), 39520–27. -
Bevacizumab improves quality of life in patients with recurrent glioblastoma.
Nagpal, S., Harsh, G., & Recht, L. (2011). Bevacizumab improves quality of life in patients with recurrent glioblastoma. Chemotherapy Research and Practice, 2011, 602812-? -
Metabolite kinetics in C6 rat glioma model using magnetic resonance spectroscopic imaging of hyperpolarized [1-13C]pyruvate
Park, J. M., Josan, S., Jang, T., Merchant, M., Yen, Y.-F., Hurd, R. E., … Mayer, D. (2012). Metabolite kinetics in C6 rat glioma model using magnetic resonance spectroscopic imaging of hyperpolarized [1-13C]pyruvate. MAGNETIC RESONANCE IN MEDICINE, 68(6), 1886–93. -
Alterations in Cerebrospinal Fluid Proteins in a Presymptomatic Primary Glioma Model
Whitin, J. C., Jang, T., Merchant, M., Yu, T. T. S., Lau, K., Recht, B., … Recht, L. (2012). Alterations in Cerebrospinal Fluid Proteins in a Presymptomatic Primary Glioma Model. PLOS ONE, 7(11). -
Thrombin-cleaved Fragments of Osteopontin Are Overexpressed in Malignant Glial Tumors and Provide a Molecular Niche with Survival Advantage
Yamaguchi, Y., Shao, Z., Sharif, S., Du, X.-Y., Myles, T., Merchant, M., … Leung, L. L. K. (2013). Thrombin-cleaved Fragments of Osteopontin Are Overexpressed in Malignant Glial Tumors and Provide a Molecular Niche with Survival Advantage. JOURNAL OF BIOLOGICAL CHEMISTRY, 288(5), 3097–3111. -
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.
Thomas, R. P., Recht, L., & Nagpal, S. (2013). Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clinical Pharmacology : Advances and Applications, 5, 1–9. -
Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized C-13 magnetic resonance spectroscopic imaging
Park, J. M., Recht, L. D., Josan, S., Merchant, M., Jang, T., Yen, Y.-F., … Mayer, D. (2013). Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized C-13 magnetic resonance spectroscopic imaging. NEURO-ONCOLOGY, 15(4), 433–41. -
Steroid-Sparing Effect of Corticorelin Acetate in Peritumoral Cerebral Edema Is Associated With Improvement in Steroid-Induced Myopathy
Recht, L., Mechtler, L. L., Wong, E. T., O'Connor, P. C., & Rodda, B. E. (2013). Steroid-Sparing Effect of Corticorelin Acetate in Peritumoral Cerebral Edema Is Associated With Improvement in Steroid-Induced Myopathy. JOURNAL OF CLINICAL ONCOLOGY, 31(9), 1182–87. -
Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI.
Schmiedeskamp, H., Andre, J. B., Straka, M., Christen, T., Nagpal, S., Recht, L., … Bammer, R. (2013). Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI. Journal of Cerebral Blood Flow and Metabolism , 33(5), 732–43. -
ETIRINOTECAN PEGOL DNA Topoisomerase 1 Inhibitor Oncolytic
Nagpal, S., & Recht, L. D. (2013). ETIRINOTECAN PEGOL DNA Topoisomerase 1 Inhibitor Oncolytic. DRUGS OF THE FUTURE, 38(4), 227–233. -
MOTEXAFIN GADOLINIUM COMBINED WITH PROMPT WHOLE BRAIN RADIOTHERAPY PROLONGS TIME TO NEUROLOGIC PROGRESSION IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES: RESULTS OF A PHASE III TRIAL
Mehta, M. P., Shapiro, W. R., Phan, S. C., Gervais, R., Carrie, C., Chabot, P., … Renschler, M. F. (2009). MOTEXAFIN GADOLINIUM COMBINED WITH PROMPT WHOLE BRAIN RADIOTHERAPY PROLONGS TIME TO NEUROLOGIC PROGRESSION IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES: RESULTS OF A PHASE III TRIAL. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 73(4), 1069–76. -
VERUBULIN HYDROCHLORIDE Apoptosis Inducer Vascular Disrupting Agent Oncolytic
Thomas, P., & Recht, L. (2010). VERUBULIN HYDROCHLORIDE Apoptosis Inducer Vascular Disrupting Agent Oncolytic. DRUGS OF THE FUTURE, 35(12), 993–997. -
Isolation of immortalized, INK4a/ARF-deficient cells from the subventricular zone after in utero N-ethyl-N-nitrosourea exposure
Savarese, T. M., Jang, T., Low, H. P., Salmonsen, R., Litofsky, N. S., Matijasevic, Z., … Recht, L. D. (2005). Isolation of immortalized, INK4a/ARF-deficient cells from the subventricular zone after in utero N-ethyl-N-nitrosourea exposure. JOURNAL OF NEUROSURGERY, 102(1), 98–108. -
EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors
Li, L., Dutra, A., Pak, E., Labrie, J. E., Gerstein, R. M., Pandolfi, P. P., … Ross, A. H. (2009). EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. NEURO-ONCOLOGY, 11(1), 9–21. -
Preliminary use of differential scanning calorimetry of cerebrospinal fluid for the diagnosis of glioblastoma multiforme
Chagovetz, A. A., Jensen, R. L., Recht, L., Glantz, M., & Chagovetz, A. M. (2011). Preliminary use of differential scanning calorimetry of cerebrospinal fluid for the diagnosis of glioblastoma multiforme. JOURNAL OF NEURO-ONCOLOGY, 105(3), 499–506. -
Understanding the Origins of Gliomas and Developing Novel Therapies: Cerebrospinal Fluid and Subventricular Zone Interplay
Glantz, M., Kesari, S., Recht, L., Fleischhack, G., & Van Horn, A. (2009). Understanding the Origins of Gliomas and Developing Novel Therapies: Cerebrospinal Fluid and Subventricular Zone Interplay. SEMINARS IN ONCOLOGY, 36(4), S17–S24. -
Gender Disparity in the Rate of Partner Abandonment in Patients With Serious Medical Illness
Glantz, M. J., Chamberlain, M. C., Liu, Q., Hsieh, C.-C., Edwards, K. R., Van Horn, A., & Recht, L. (2009). Gender Disparity in the Rate of Partner Abandonment in Patients With Serious Medical Illness. CANCER, 115(22), 5237–42. -
Aberrant nestin expression during ethylnitrosourea-(ENU)-induced neurocarcinogenesis
Jang, T. C., Litofsky, N. S., Smith, T. W., Ross, A. H., & Recht, L. D. (2004). Aberrant nestin expression during ethylnitrosourea-(ENU)-induced neurocarcinogenesis. NEUROBIOLOGY OF DISEASE, 15(3), 544–552. -
Differentiation prevents assessment of neural stem cell pluripotency after blastocyst injection
Greco, B., Low, H. P., Johnson, E. C., Salmonsen, R. A., Gallant, J., Jones, S. N., … Recht, L. D. (2004). Differentiation prevents assessment of neural stem cell pluripotency after blastocyst injection. STEM CELLS, 22(4), 600–608. -
Central Nervous System Cancers
Brem, S. S., Bierman, P. J., Brem, H., Butowski, N., Chamberlain, M. C., Chiocca, E. A., … Wen, P. Y. (2011). Central Nervous System Cancers. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(4), 352–400. -
Embryonic stem cell rescue of tremor and ataxia in myelin-deficient shiverer mice
Low, H. P., Greco, B., Tanahashi, Y., Gallant, J., Jones, S. N., Billings-Gagliardi, S., … Schwartz, W. J. (2009). Embryonic stem cell rescue of tremor and ataxia in myelin-deficient shiverer mice. JOURNAL OF THE NEUROLOGICAL SCIENCES, 276(1-2), 133–137. -
Central Nervous System Cancers Clinical Practice Guidelines in Oncology
Nabors, L. B., Ammirati, M., Bierman, P. J., Brem, H., Butowski, N., Chamberlain, M. C., … Ho, M. (2013). Central Nervous System Cancers Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(9), 1114–1151. -
Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D Delta R-2-mu MRA
Lin, C.-Y., Siow, T. Y., Lin, M.-H., Hsu, Y.-H., Tung, Y.-Y., Jang, T., … Chang, C. (2013). Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D Delta R-2-mu MRA. ANGIOGENESIS, 16(4), 785–793. -
Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D Delta R-2-mu MRA
Lin, C.-Y., Siow, T. Y., Lin, M.-H., Hsu, Y.-H., Tung, Y.-Y., Jang, T., … Chang, C. (2013). Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D Delta R-2-mu MRA. ANGIOGENESIS, 16(4), 785–793. -
Monitoring of cancer ferroptosis with [(18)F]hGTS13, a system xc- specific radiotracer.
Moses, A. (2025). Monitoring of cancer ferroptosis with [(18)F]hGTS13, a system xc- specific radiotracer. Theranostics. -
Deuterium metabolic imaging for 3D mapping of glucose metabolism in humans with central nervous system lesions at 3T.
Adamson, P. (2024). Deuterium metabolic imaging for 3D mapping of glucose metabolism in humans with central nervous system lesions at 3T. Magn Res Med. -
Deuterium metabolic imaging for 3D mapping of glucose metabolism in humans with central nervous system lesions at 3T.
Kendirli, M. (2023). Deuterium metabolic imaging for 3D mapping of glucose metabolism in humans with central nervous system lesions at 3T. Nucl Med Bio. -
A clinical PET Imaging Tracer ([18F]DASA-23) to monitor pyruvate kinase M2-induced glycolytic reprogramming in glioblastoma
Beinat, C. (2021). A clinical PET Imaging Tracer ([18F]DASA-23) to monitor pyruvate kinase M2-induced glycolytic reprogramming in glioblastoma. Clinical Cancer Research. -
High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells.
J, S. (2020). High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells. . Scientific Reports. -
A proteomic clock for malignant gliomas: The role of the environment in tumorigenesis at the presymptomatic stage
Zheng, L. (2019). A proteomic clock for malignant gliomas: The role of the environment in tumorigenesis at the presymptomatic stage. PLOS One. -
Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making.
Iv, M. (2019). Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making. Am J Neuroradiol. -
Reversed metabolic reprogramming as a measure of cancer treatment efficacy in rat C6 glioma model.
Datta, K. (2019). Reversed metabolic reprogramming as a measure of cancer treatment efficacy in rat C6 glioma model. PLOS One. -
Macrophage exclusion after radiation therapy (MERT): A first in human Phase I/II trial using a CXCR4 inhibitor in Glioblastoma
Thomas, R. (2019). Macrophage exclusion after radiation therapy (MERT): A first in human Phase I/II trial using a CXCR4 inhibitor in Glioblastoma. Clinical Cancer Research. -
Phase I study of MED3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors
Hyman, D. (2018). Phase I study of MED3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors. Clinical Cancer Research. -
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRviii-expressing glioblastoma (ACT IV): a randomized, double-blind, international phase 3 trial.
Weller, M. (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRviii-expressing glioblastoma (ACT IV): a randomized, double-blind, international phase 3 trial. Lancet Oncology. -
Optimizing bevacizumab dosing in glioblastoma: less is more.
Ajlan, A. (2017). Optimizing bevacizumab dosing in glioblastoma: less is more. J Neuro-Oncology. -
Phase ½ trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma: Health-related quality of life results
Pollom, E. (2017). Phase ½ trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma: Health-related quality of life results. Int J Radiat Oncol Bio Physic. -
Randomized, double-bline, placebo-controlled, multicenter Phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent gliolblastoma: Efficacy, safety, and hepatocyte growth factor and O6-methylguanine-DNA methyltransferase biomarker analyses.
Cloughesy, T. (2016). Randomized, double-bline, placebo-controlled, multicenter Phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent gliolblastoma: Efficacy, safety, and hepatocyte growth factor and O6-methylguanine-DNA methyltransferase biomarker analyses. J Clinical Oncology. -
SDF-1 blockade enhances anti-VEGF therapy of glioblastoma and can be monitored by MRI.
Deng, L. (2016). SDF-1 blockade enhances anti-VEGF therapy of glioblastoma and can be monitored by MRI. Neoplasia. -
Hyperpolarized 13 C-lactate to 13 C-bicarbonate ratio as a biomarker for monitoring the acute response of anti-vascular endothelial growth factor (anti-VEGF) treatment
Park, J. (2016). Hyperpolarized 13 C-lactate to 13 C-bicarbonate ratio as a biomarker for monitoring the acute response of anti-vascular endothelial growth factor (anti-VEGF) treatment. NMR Biomed. -
Cerebro spinal fluid protein dynamic drive network: at the crossroads of brain tumorigenesis.
Tan, Z. (2015). Cerebro spinal fluid protein dynamic drive network: at the crossroads of brain tumorigenesis. Methods. -
Glioblastoma multiforme recurrence: An exploratory study of 18F FRPPRGD2 PET/CT
Iagaru, A. (2015). Glioblastoma multiforme recurrence: An exploratory study of 18F FRPPRGD2 PET/CT. Radiology. -
Volumetric spiral chemical shift imaging of hyperpolarized [2-13C]pyruvate in a rat C6 glioma model
Park, J. (2015). Volumetric spiral chemical shift imaging of hyperpolarized [2-13C]pyruvate in a rat C6 glioma model. Magnetic Res Imaging. -
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
nagpal, S. (2015). Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. J Neuro-Oncology. -
Cerebral blood flow changes in glioblastoma patients undergoing bevacizumab treatment are seen in both tumor and normal brain
Andre, J. (2015). Cerebral blood flow changes in glioblastoma patients undergoing bevacizumab treatment are seen in both tumor and normal brain. Neurorad J. -
Gamma-glutamyl transferase 7 is a novel regulator of glioblastoma growth
Bui, T. (2015). Gamma-glutamyl transferase 7 is a novel regulator of glioblastoma growth. BMC Cancer. -
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
Schuster, J. (2014). A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. NeuroOncology. -
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochtonous brain tumors in rats
Liu, S. (2013). Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochtonous brain tumors in rats. Neuro-Oncology. -
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
Walters, M. (2014). Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer.
-
High-resolution genome-wide mapping of genetic alterations in human glial brain tumors
Clinical Trials
Clinical trials are ÌÇÐÄ´«Ã½ studies that evaluate a new medical approach, device, drug, or other treatment. As a ÌÇÐÄ´«Ã½ patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
- Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
- Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
- XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
- A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
- Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
- 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
- XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Practice Locations
Brain and Spine Tumor Center at Stanford Cancer Center Palo Alto, CA
Palo Alto, CA
Brain and Spine Tumor Center at Stanford Cancer Center
875 Blake Wilbur Dr, Clinic D
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereNeurogenetic Cancer Palo Alto, CA
Palo Alto, CA
Neurogenetic Cancer
213 Quarry Rd
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri- Valley, or Stanford Medicine Partners. ÌÇÐÄ´«Ã½, ÌÇÐÄ´«Ã½ Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(101 reviews)
Very nice, obviously experienced, oncologist. I feel like some of both my wishes and his to help keep this ogre in my head in check (GBM), is impedes by Stanford. The continuity of care for me as a patient, is awful. Where’s the “Medical Trials Team exactly at? The patient feels forgotten/dispensible.
Clear, knowledgeable and helpful.
Awesome doctor!
As a patient, very easy to engage Dr. Recht in conversations about my medical condition and care options.
Think Dr. Recht great doctor
A very productive discussion.
Very clean
Good doctor directors are very efficient direct listens and communicates well and we get along and he knows my case and is really involved in it
I always recommend Stanford and all their departments. All have been top notch.
Excellent provider, very knowledgeable, good at explaining, and listens well.
Great doctor! I am so grateful to have had a caring and knowledgeable neurologist throughout my Brain cancer journey.
He is extremely knowledgeable and shows real concern for the patient. I feel fortunate to have him as my doctor.
Great physician and communicator
Dr. Recht and NP Eleanor are excellent clinicians. I'm very grateful for the care they gave me today. I've been seeing Dr. Recht since my cancer diagnosis in 2005. Dr. Recht and his team are superb. I'm truly blessed to have Dr. Recht treat me all these years. He provided health care notes to help me obtain permanent disability from the SSA and annual updates regarding my current condition so that I continue to receive LTD benefits from my company's LTD benefit provider.
Thank you Dr. Recht!!
Dr. Recht explained everything very clearly and was wonderful.
Dr. REcht and his office have gone above and beyond to be empathetic to our concern and urgency.
The doctor and his assistant took special care to explain things
Wonderful doctor, we feel blessed
Dr was very thorough asking and answering questions.
Dr.Recht made me feel comfortable and was easy to about what is happening to me..
He and his staff have ALWAYS been caring and informative. They invite us to talk and answer questions
communicates the important info
A caring doctor, he explains the reasons for and the results of any tests he calls. He makes sure any questions are answered and sets perimeters for future visits
Great doctor. Very understanding and responsive.
Always good
Kind and understanding and very informative
I would recommend him to anyone. I found him empathic and knowledgeable, easy to communicate with, and it was a pleasure to see how he worked, meaning, I learned a great deal by paying attention to the kinds of questions he asked my husband and about my husband in order to form a coherent picture of what might be going on with him.
In the after visit I also appreciated his direct approach, in the way he presented our situation in a way that was honest without being cruel. I found him deeply respectful of my husband and myself, something unusual these days, and for that we both are grateful.
Very helpful. Good clear communication and direction.
Fantastic physician
Everything is very well covered !
Dr. Recht is the best
I am fortunate to have Dr. Recht, a brilliant physician, managing my tumor. When he leaves the room, it is his smile and subtle humor that makes me feel I am going to be okay.
Very caring, thorough and helpful. Great doctor!
Dr. Recht is attentive, patient and caring.
Great doctor, always explains things clearly
Very efficient and effective. Had examined and compared tests well. Difficulty in deciding whether to continue or not the Avastin treatments was answered, but I was still not sure the problems that my husband might incur as a result of discontinuing them temporarily.
He’s a wonderful doctor and I feel lucky to be in his care
I love Dr Lawrence Recht. He genuinely cares for my overall well being.
Wonderful doctor!
Gave good advice for future treatment.
An excellent doctor who explains everything in a manner which is understandable to a patient. He is professional and caring.
Dr. Recht is a great doctor. He does tend to run late most of the time. This time he was an hour late, which is about the longest I have had to wait.
I like, respect and trust Dr. Recht and am grateful for his help.
Wonderful doctor who always explains things very throughly
Dr. Recht is great!
Doctor is superb.
Very caring & knowledgeable doctor - strength - explanations that the patient can understand.
Dr. Recht has been great every time!
Dr. Recht is the best!
You're the BEST!
Very good doctor and "residents." Very good nurses.
Overall good.
Extremely high confidence in Dr. Recht.
Best oncologist I could ask for and the reason I have stayed with Stanford despite travel demands. Very thankful Dr. Recht is my doctor.
Patients time is just as important as everyone else.
Dr. Recht provides excellent information in terms of interpreting test results (MRI) and expectations for going toward expectations. His medical insights give us confidence in understanding the current status and sometimes subtleties of the medical condition.
Dr. Recht & assistant Dr. Boah excellent.
Great experience.
Extraordinarily knowledgeable. Described treatment trade-offs more clearly & in-depth than any of our other second opinions.
Dr. Recht is awesome!
My first time at Stanford in which my husband and I didn't leave with unanswered questions. Dr. Recht was very thorough and matter of fact yet kind and compassionate to my unique circumstances.
Always good.
Dr. Tresa M. Granalan was exceptional!
Dr. Recht is very good.
Physician is very attentive and very helpful.
An all around positive experience during a rather stressful time.
I would recommend because the attention given & the confidence they make the patient & fam. feel.
I was very comfortable with Dr. Recht and his assistant or nurse, "Megan".
Dr. Recht has always treated me w/respect. His is my go to person when other doctors have changed my medicine therapy. He has kept me alive long after the disease should have taken me.
Saved my life.
Dr. Recht & Gwen are the best."
EXCELLENT.
Can't expect a doctor to be too friendly when delivering bad news. He was very professional.
I have absolute confidence in these people.
Dr. Recht is a wonderful doctor; I feel very comfortable with him and confident about his abilities as a physician.
I am totally proud to have this hospital as my clinic I give thanks to God for that.
Saw the assistant much longer than doctor.
The best doctor I have ever had in the last 40 years.
The fellow I saw was great, but Recht barely stepped into the room & didn't seem to be all there mentally.
Sometimes physicians need to speak more straight forwardly.
Dr. Corbin is so helpful, listens to all concerns and very informative fellow working with Dr. Recht.
I had a great experience. It was overall good.
Dr. Recht is a wonderful physician. He is highly intelligent, yet he is able to speak to the patient's level of understanding.
I valued the time Dr. Recht spent with me. He listened to the patient and explained clearly about the problem.
Dr. Recht is one of the highest rated doctor's I deal with across the board. I wish I could get another department (example: Stanford Urology) to even come close to any of the Stanford neuro or Stanford E.N.T. doctors I'm taken care of under.
Dr. Recht is the "stud" of neuro's!
Dr. Recht is the BEST!
Both Gwen & Dr. Recht showed patience, care, encouragement & deep understanding & compassion on a day that was very hard & emotional for me.
good
Dr. Recht has an uncanny ability to converse with me. Thank you for your insight & thoughtfulness in my health care over the years.
The best medical care I could have expected. Dr. Recht also called, in a radiation oncologist to do a preliminary eval. which resulted in updated MRI needed ASAP.
Dr. Recht & his entire staff are terrific.
I am very happy with Dr. Recht and couldn't ask for a better oncologist.
Medication called in to pharmacy with incorrect instructions. Chemo cycle was stopped without telling me (I had asked if it could be temporarily stepped) with no further discussion (found out a week later).
When I go there I know every thing is going to be fine.
All experiences were good.
Dr. Recht is compassionate, kind, informative & reassuring I have the highest confidence in being his patient.
Very good.
Excellent!
Somewhat good.
Dr. Recht is very personable & relaxed. At same time professional & knowledgeable. Spends appropriate amt of time.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone:Ìý1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
ÌÇÐÄ´«Ã½ provides comprehensive services toÌýreferÌýandÌýtrack patients, as well as the latest information and news for physicians and office staff.ÌýFor help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
Ìý
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records